Biology of Blood and Marrow Transplantation
Volume 14, Issue 2 , Pages 236-245 , February 2008

Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning

  • Parameswaran Hari

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • Corresponding Author InformationCorrespondence and reprint requests: Parameswaran Hari, MD, CIBMTR, Medical College of Wisconsin, P.O. Box 26509, Milwaukee, WI 53226.
    • ,
  • Jeanette Carreras

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Mei-Jie Zhang

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Robert Peter Gale

      Affiliations

    • Center for Advanced Studies in Leukemia, Los Angeles, California
    • ,
  • Brian J. Bolwell

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Christopher N. Bredeson

      Affiliations

    • Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Linda J. Burns

      Affiliations

    • University of Minnesota, Minneapolis, Minnesota
    • ,
  • Mitchell S. Cairo

      Affiliations

    • Children's Hospital of New York Presbyterian, New York, New York
    • ,
  • César O. Freytes

      Affiliations

    • University of Texas Health Science Center, San Antonio, Texas
    • ,
  • Steven C. Goldstein

      Affiliations

    • University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Gregory A. Hale

      Affiliations

    • St. Jude Children's Research Hospital, Memphis, Tennessee
    • ,
  • David J. Inwards

      Affiliations

    • Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • Charles F. LeMaistre

      Affiliations

    • Texas Transplant Institute, San Antonio, Texas
    • ,
  • Dipnarine Maharaj

      Affiliations

    • South Florida Bone Marrow Stem Cell Transplant Institute, Boynton Beach, Florida
    • ,
  • David I. Marks

      Affiliations

    • Bristol Children's Hospital, Bristol, United Kingdom
    • ,
  • Harry C. Schouten

      Affiliations

    • University Hospital Maastricht, Maastricht, The Netherlands
    • ,
  • Shimon Slavin

      Affiliations

    • Hadassah-Hebrew University Hospital, Jerusalem, Israel
    • ,
  • Julie M. Vose

      Affiliations

    • University of Nebraska Medical Center, Omaha, Nebraska
    • ,
  • Hillard M. Lazarus

      Affiliations

    • Case Western Reserve University, Cleveland, Ohio
    • ,
  • Koen van Besien

      Affiliations

    • University of Chicago, Chicago, Illinois

Received 12 October 2007 ,Accepted 13 November 2007.

References 

  1. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13:140–147
  2. van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998;92:1832–1836
  3. van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521–3529
  4. Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Program). 2001;375–391
  5. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  6. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104:3865–3871
  7. Khouri IF, Champlin RE. Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol. 2004;31:22–26
  8. Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood. 2004;103:428–434
  9. Medeiros B, Nieto Y, Bearman S, et al. Fatal aplasia and graft rejection after nonmyeloablative allografting. [abstract] Blood. 2002;100:#1613
  10. Thomas ED, Herman EC, Cannon JH, et al. Autogenous recovery of marrow function. Recovery after general exposure to 1082 roentgens of Co60 radiation at 36 roentgens per hour. Arch Intern Med. 1961;107:395–400
  11. Branch DR, Gallagher MT, Forman SJ, Winkler KJ, Petz LD, Blume KG. Endogenous stem cell repopulation resulting in mixed hematopoietic chimerism following total body irradiation and marrow transplantation for acute leukemia. Transplantation. 1982;34:226–228
  12. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–637
  13. Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–846
  14. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007;109:3588–3594
  15. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York: Springer; 2003;
  16. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457–481
  17. Zhang MJ, Klein JP. Confidence bands for the difference of 2 survival curves under proportional hazards model. Lifetime Data Anal. 2001;7:243–254
  18. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359:1309–1310
  19. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant. 2001;28:1001–1011
  20. van Besien KW, Khouri IF, Giralt SA, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol. 1995;13:1096–1102
  21. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310–4316
  22. Maris MB, Sandmaier BM, Storer B, et al. Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma. ASH Annu Meet Abstr. 2005;106:1130
  23. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004;104:1550–1558
  24. Vigouroux S, Michallet M, Socie G, et al. Allogeneic stem cell transplantation with reduced intensity conditioning for the treatment of patients with relapsed low-grade lymphoma: a report of the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). [abstract] Bone Marrow Transplant. 2006;37:#241
  25. Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12:1326–1334
  26. Devetten MP, Hari P, Carerras J, et al. Unrelated donor nonmyeloablative/reduced intensity (NST/RIC) hematopoietic stem cell transplantation (HCT) for patients with relapsed and refractory Hodgkin's lymphoma (HL). ASH Ann Meet Abstr. 2006;108:601
  27. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104:961–968
  28. Schmitz N, Eapen M, Horowitz MM, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood. 2006;108:4288–4290
  29. Anderson D, DeFor T, Burns L, et al. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections. Biol Blood Marrow Transplant. 2003;9:52–59
  30. Dreger P, Brand R, Milligan D, et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia. 2005;19:1029–1033

PII: S1083-8791(07)00573-3

doi: 10.1016/j.bbmt.2007.11.004

Biology of Blood and Marrow Transplantation
Volume 14, Issue 2 , Pages 236-245 , February 2008

Article Tools

* Image Usage & Resolution